This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Omuro, A. M.P. Articles by Raymond, E. Search for Related Content PubMed PubMed Citation Articles by Omuro, A. M.P. Articles by Raymond, E. Related Collections Therapeutics and Targets: Experimental Therapeutics– Small Molecules Clinical Research Clinical Research: Clinical Trials

Reviews

Lessons learned in the development of targeted therapy for malignant gliomas

¹ AP-HP Hopital Pitie-Salpetriere, Service de Neurologie Mazarin; Universite Paris VI Pierre et Marie Curie, IFR 70; INSERM, U711, Paris, France and ² AP-HP Hopital Beaujon, Service Inter-Hospitalier Cancerologie, Clichy, France

Requests for reprints: Antonio M.P. Omuro, Groupe Hospitalier Pitie-Salpetriere-Federation de Neurologie Mazarin 47, Bd de l'Hopital, 75661 Paris Cedex 13, France. Phone: 33-1-42-16-41-60; Fax: 33-1-42-16-03-75. E-mail: antonio.omuro{at}psl.aphp.fr

The prognosis of patients with glioblastoma, anaplastic astrocytoma, and anaplastic oligodendroglioma remains poor despite standard treatment with radiotherapy and temozolomide. Molecular targeted therapy holds the promise of providing new, more effective treatment options with minimal toxicity. However, the development of targeted therapy for gliomas has been particularly challenging. The oncogenetic process in such tumors is driven by several signaling pathways that are differentially activated or silenced with both parallel and converging complex interactions. Therefore, it has been difficult to identify prevalent targets that act as key promoters of oncogenesis and that can be successfully addressed by novel agents. Several drugs have been tested, including epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (gefitinib and erlotinib), mammalian target of rapamycin (mTOR) inhibitors (temsirolimus and everolimus), and vascular endothelial growth factor receptor (VEGFR), protein kinase C-ß, and other angiogenesis pathways inhibitors (vatalanib, bevacizumab, and enzastaurin). Although preliminary efficacy results of most trials in recurrent disease have fallen short on expectations, substantial advances have been achieved by associated translational research. In this article, we seek to recapitulate the lessons learned in the development of targeted therapy for gliomas, including challenges and pitfalls in the interpretation of preclinical data, specific issues in glioma trial design, insights provided by translational research, changes in paradigms, and future perspectives. [Mol Cancer Ther 2007;6(7):1909–19]

This article has been cited by other articles:

				S. M. Chang, K. R. Lamborn, J. G. Kuhn, W.K. A. Yung, M. R. Gilbert, P. Y. Wen, H. A. Fine, M. P. Mehta, L. M. DeAngelis, F. S. Lieberman, et al. Neurooncology clinical trial design for targeted therapies: Lessons learned from the North American Brain Tumor Consortium Neuro-oncol, August 1, 2008; 10(4): 631 - 642. [Abstract] [Full Text] [PDF]

				S. Wang, P. Guo, X. Wang, Q. Zhou, and J. M. Gallo Preclinical pharmacokinetic/pharmacodynamic models of gefitinib and the design of equivalent dosing regimens in EGFR wild-type and mutant tumor models Mol. Cancer Ther., February 1, 2008; 7(2): 407 - 417. [Abstract] [Full Text] [PDF]